Health Care Archives - Page 452 of 478

1 minute read

Rain Therapeutics Concludes Enrolment In Late-Stage Tissue Cancer Study, Expects Topline Data In H1 2023

August 4, 12:37 PM

Rain Therapeutics (NASDAQ: RAIN) has completed patient enrolment in its Phase 3 MANTRA trial of its lead asset, milademetan for well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS).

RAIN

1 minute read

Zoetis’s Clocks Mixed Q2 Earnings, Lowers FY22 Profit Outlook

By Vandana Singh

August 4, 12:23 PM

Zoetis Inc (NYSE: ZTS) has reported Q2 FY22 revenue of $2.05 billion, an increase of 5% Y/Y, almost in line with…

ZTS

1 minute read

Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings

By Vandana Singh

August 4, 12:18 PM

Organon & Co’s (NYSE:OGN) Q2 sales decreased 1% Y/Y to $1.59 billion, beating the consensus of $1.54 billion. The sales…

OGN

2 minute read

ChemoCentryx Shares Are Jumping 110% Thursday: Here’s Why

By Dylan Wechsler

August 4, 12:18 PM

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

AMGN

1 minute read

Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm

By Vandana Singh

August 4, 12:13 PM

Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists…

GILD

2 minute read

FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder

By Vandana Singh

August 4, 12:11 PM

The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…

BCRX

1 minute read

Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end

By Ragothaman Srinivasan

August 4, 12:03 PM

Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.

ATXS

1 minute read

FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication

By Vandana Singh

August 4, 7:36 AM

Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.

TVTX